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Abstract
Background Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, 
progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on 
gene panel testing or whole-exome/genome sequencing.
Methods Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed 
whole-exome sequencing in the two patients and their mother.
Results Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual 
impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed 
scoliosis, leading to respiratory problems. In their late 30’s, both siblings developed a hypertrophic cardiomyopathy and 
died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous 
c.627_629del; p.(Gly210del) deletion in UCHL1.
Conclusions The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional 
feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and 
treatment in neurodegenerative disease associated with UCHL1 mutations.
Keywords Neurogenetics · Behr syndrome · Hereditary spastic paraplegia · Ataxia · Whole exome sequencing
Introduction
Hereditary spastic paraplegias (HSP) are a clinically and 
genetically diverse group of disorders characterized by pro-
gressive lower limb spasticity. Inheritance can be dominant, 
recessive or X-linked, or rarely mitochondrial [1]. Additional 
neurological manifestations include optic atrophy, cerebel-
lar ataxia, and peripheral neuropathy [2]. SPG79 is caused 
by homozygous or compound heterozygous mutations in 
UCHL1, which encodes Ubiquitin C‐terminal hydrolase‐L1. 
 * Rita Horvath 
 rh732@medschl.cam.ac.uk
1 Department of Neurosciences, Royal Victoria Hospital, 
Belfast, UK
2 Department of Neuropediatrics and Muscle Disorders, 
Faculty of Medicine, Medical Center – University 
of Freiburg, Freiburg, Germany
3 Centro Nacional de Análisis Genómico (CNAG-CRG), 
Center for Genomic Regulation, Barcelona Institute 
of Science and Technology (BIST), Barcelona, Catalonia, 
Spain
4 Division of Neurology, Department of Medicine, Children’s 
Hospital of Eastern Ontario Research Institute, The Ottawa 
Hospital and Brain and Mind Research Institute, University 
of Ottawa, Ottawa, Canada
5 Wellcome Centre for Mitochondrial Research, Translational 
and Clinical Research Institute, Newcastle University, 
Newcastle upon Tyne, UK
6 GKT School of Medical Education, King’s College London, 
London, UK
7 Department of Clinical Neurosciences, University 
of Cambridge School of Clinical Medicine, Cambridge 
Biomedical Campus, Cambridge, UK
8 MRC Mitochondrial Biology Unit, University of Cambridge, 
Cambridge, UK
9 Department of Clinical Neurosciences, University 
of Cambridge School of Clinical Medicine, John Van 
Geest Cambridge Centre for Brain Repair, Robinson Way, 
Cambridge CB2 0PY, UK
3644 Journal of Neurology (2020) 267:3643–3649
1 3
In addition to spasticity, ataxia, and peripheral neuropathy, 
SPG79 is characterized by severe optic atrophy in the first 
decade of life. To date, mutations in UCHL1 have been 
described in only three families [3–5].
Using whole exome sequencing, we have identified a 
further family with SPG79, carrying a novel homozygous 
deletion in UCHL1. Both siblings presented in childhood 
with motor developmental delay, optic atrophy leading to 
progressive visual loss, cerebellar ataxia, spastic paraparesis, 
and motor neuropathy. Intriguingly, both siblings also devel-
oped hypertrophic cardiomyopathy, a potentially modifiable 
clinical feature which has not been described in association 
with SPG79 before.
Patients and methods
Patient 1 (P1) and Patient 2 (P2) were born to British par-
ents from the North of England. There is no information on 
consanguinity. P1 was the product of a normal pregnancy 
and was born at full-term, and had normal early develop-
ment. She first presented aged 8 years with visual problems 
and optic atrophy was detected. Her motor function gradu-
ally deteriorated over the next years and she developed pro-
gressive lower limb spasticity, foot deformities, and severe 
scoliosis requiring spinal surgery aged 16 years. Cognitive 
function was normal. She became non-ambulant following 
a femoral fracture aged 38 years. From the age of 39, she 
developed nocturnal hypoventilation and was commenced 
on overnight non-invasive ventilation.
On examination aged 41 years (Fig. 1a), she had facial 
dysmorphism including low nasal bridge, micrognathia, 
and large, low-set ears, bilateral optic atrophy and severely 
reduced visual acuity, but no ophthalmoparesis or nystag-
mus. Deep tendon reflexes were absent in the upper and 
lower limbs, and there was length-dependent atrophy and 
sensory loss in-keeping with a peripheral neuropathy. She 
had marked lower limb spasticity, extensor plantar responses 
and ankle clonus, and a severe scoliosis.
P2, her younger brother, also presented in early child-
hood with reduced visual acuity. He developed lower limb 
spasticity, contractures, and foot deformity. He became non-
ambulant aged 8 years following surgical correction of his 
foot deformity. His visual acuity continued to deteriorate due 
to optic atrophy, so that he was functionally blind. Cognitive 
function was also unaffected in P2.
Examination of P2 aged 33 (Fig. 1a) revealed bilateral 
optic atrophy, both pendular and gaze induced nystagmus, 
ophthalmoparesis, facial dysmorphism including low nasal 
bridge, micrognathia and large, low-set ears, and facial hypo-
tonia. Deep tendon reflexes were pathologically reduced in 
upper and lower limbs, and plantar responses were exten-
sor. Sensation was intact. He had severe finger–nose ataxia, 
dysdiadochokinesia, and truncal ataxia.
Detailed laboratory work-up (including acylcarnitines, 
urinary organic acids, very long chain fatty acids, pristanic 
Fig. 1  a P1 aged 40 years (left) and P2 aged 38 years. Both patients 
have characteristic facial features low-set ears and, and presented with 
distal upper and lower limb wasting and equinovarus deformity due 
to peripheral neuropathy and spastic paraparesis. b Axial T2 FLAIR 
MR images of P1 (top panels) and P2 (bottom panels). MRI brain in 
P1 aged 41 years showed mild global atrophy. MRI brain in P2 aged 
34 demonstrated no significant abnormality apart from mild increased 
T2 signal in the peritrigonal white matter bilaterally
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and phytanic acids, lysosomal enzymes, copper, caeruloplas-
min, and acanthocytes) was normal. CSF constituents were 
normal in both cases. MRI brain in P1 aged 41 years showed 
mild global atrophy and a small focus of non-specific perive-
ntricular T2 signal change at the right frontal horn (Fig. 1b). 
MRI brain in P2 aged 34 (Fig. 1b) demonstrated no signifi-
cant abnormality apart from mild increased T2 signal in the 
peritrigonal white matter bilaterally. Unfortunately, neuro-
physiological testing was not technically possible due to the 
degree of foot deformity and swelling. Direct sequencing of 
FXN revealed no candidate pathogenic variants. Fifty-six 
gene inherited peripheral neuropathy panel (Bristol genet-
ics laboratory) which also failed to identify any pathogenic 
variants and a comparative genomic hybridization (CGH) 
array was normal.
Given the symptomatic features of a possible mitochon-
drial disorder, in particular optic atrophy, a cardiac evalua-
tion was carried out in both patients. Echocardiogram in P2 
aged 33 years revealed a small, globally hypertrophied left-
ventricular cavity, left-ventricular systolic ejection gradient 
(36 mmHg), and impaired diastolic left-ventricular function. 
Echocardiogram in P1 aged 41 years was technically difficult 
due to severe scoliosis, but also demonstrated cardiomyopa-
thy, with moderately impaired left-ventricular function. The 
left-ventricular posterior wall was hypokinetic and the inter-
ventricular septum was dyskinetic. There was no significant 
family history of sudden cardiac death, arrhythmias, heart 
failure, or young stroke.
Both siblings were commenced on ACE inhibitors and 
beta-blockers and their cardiac function stabilized. Despite 
this, both siblings developed progressive shortness of breath 
and apnoeic episodes. P1 died aged 43  years, P2 aged 
40 years, both due to sudden cardiac death.
Whole exome sequencing
WES was performed on genomic DNA in P1 and P2 and 
on their mother. Their father was deceased at the time of 
study. The genomic DNA was exome-enriched using Illu-
mina TruSeq 62 Mb exome capture and sequenced on an 
Illumina HiSeq 2000 with 100 bp paired-end reads. Standard 
filtering criteria were applied, including minor allele fre-
quency of less than 1% and high-to-moderate variant effect 
predictor (i.e., nonsense, splice site, frame-shift, in-frame, 
and non-synonymous variants). Rare homozygous and com-
pound heterozygous variants were defined, and protein alter-
ing and/or putative ‘disease causing’ mutations, along with 
their functional annotation, were identified using ANNO-
VAR. Candidate genes were prioritized if previously asso-
ciated with a disease phenotype. Genomic and phenotypic 
data have been submitted to RD-Connect Genome-Phenome 
Platform (GPAP, https ://platf orm.rd-conne ct.eu), where they 
can be accessed under a controlled access agreement.
Detection of homozygous regions
As part of the RD-Connect GPAP standard analysis pipe-
line, runs of homozygosity (ROH) were identified in each 
individual using PLINK v.1.90 [6], applying optimized 
parameters as defined by Kancheva et al. [7]. Only ROH 
with a minimum length of 1 Mbp were identified, to exclude 
common shorter ROH. Consanguinity assessment was per-
formed through application of ROH thresholds for WES as 
described in Matalonga et al. [8].
Results
WES analysis revealed the presence of a homozy-
gous  c.627_629del;  p.(Gly210del)  UCHL1  variant 
(NM_004181.5) in P1 and P2 (Fig. 2a). This variant is 
reported only once in heterozygous form in gnomAD (allele 
frequency 0.000004), but never in homozygous form. Their 
unaffected mother was heterozygous for the variant. This 
variant could disrupt substrate binding at the distal UCHL1 
site [9]. Additionally, we assessed IBD regions by the detec-
tion of > 1 Mbp runs of homozygosity (ROH). Results have 
shown that both patients carry an increased number of 
large ROH segments, 18 (P1 and P2) versus 5 from their 
mother, with a total ROH size of 76 MB (P1) and 48 MB 
(P2) respectively, underlying a possible recent consanguinity 
(Fig. 2b) [8]. Exome data were also analyzed for variants in 
genes associated with hypertrophic cardiomyopathy, but no 
potentially causative variants were detected.
Discussion
Here, we describe two siblings with clinical presentation 
comprising progressive spasticity, motor neuropathy, ataxia, 
and optic atrophy, resembling Behr syndrome, and with the 
additional clinical finding of hypertrophic cardiomyopathy. 
Whole exome sequencing identified a novel homozygous 
deletion of three nucleotides in UCHL1. Paternal data were 
not available to perform complete segregation studies and 
confirm his carrier status. However, normal CGH array 
results excluded a large chromosomal rearrangement in the 
paternal allele, and although a deletion in UCHL1 cannot be 
discarded, the possible recent consanguinity identified by 
ROH analyses support the homozygous status assumption. 
Ubiquitin C‐terminal hydrolase‐L1 (UCHL1) is critically 
important in maintaining free ubiquitin levels through the 
addition or removal of ubiquitin to poly-ubiquitin chains, 
and thus has a central role in cytoplasmic protein degra-
dation [10]. It is one of the most abundant proteins in the 
nervous system, being highly expressed in both the central 
and peripheral nervous system [11–13]. Through its close 
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interaction with the neuronal cytoskeleton, UCHL1 is 
thought to have important roles in axonal repair after injury, 
axonal transport, and synaptic function [14–16].
Mutations in UCHL1 have been described in three fami-
lies with autosomal recessive spastic paraplegia (SPG79) 
[3–5]. The phenotype of the patients in the present study 
had many similarities to the previously reported cases 
(Table 1). In all cases described to date, the first symptom 
was of childhood-onset visual loss due to optic atrophy. The 
subsequent disease course was characterized by varying 
degrees of spasticity and cerebellar ataxia. Additional, less 
consistently described features include epilepsy, cognitive 
impairment, facial myokymia, fasciculations, and reduced 
peripheral sensation, reflecting the widespread expression of 
UCHL1 in most neuronal cells. The clinical presentation of 
our patients and all previously reported cases were compat-
ible with Behr syndrome (Table 1).
First described by Carl Behr in 1909, the classical 
Behr syndrome (MIM 210000) comprises childhood-
onset optic atrophy combined with various neurologi-
cal symptoms including spastic paraparesis, ataxia, mild 
ophthalmoparesis, peripheral neuropathy, and a variable 
degree of learning difficulties [17]. While the optic atro-
phy in these patients remains stable, other neurological 
signs progress during childhood becoming more prominent 
in the second or third decades [17].
Autosomal recessive OPA3 mutations have been 
identified in Iraqi Jewish patients presenting with Behr 
syndrome and 3-methylglutaconic aciduria (Costeff syn-
drome) [18] and more recently autosomal dominant [19] 
and recessive [20] OPA1 mutations were shown in Behr 
syndrome without metabolic abnormalities. We reported 
six patients with Behr syndrome and autosomal recessive 
mutation in C12orf65 [21], and a homozygous C12orf19 
mutation has also been reported to cause this phenotype 
[22], illustrating further genetic heterogeneity of this 
phenotype. All previously reported genetic forms of Behr 
syndrome affect mitochondrial proteins involved in dif-
ferent mitochondrial functions. The detection of UCHL1 
mutations in this phenotype adds another molecular 
mechanism, protein de-ubiquitination contributing to Behr 
Fig. 2  a Pathogenic mutations identified in UCLH1. b Consanguinity analysis through run of homozygosity (ROH) > 1 Mbp detection in autoso-
mal chromosomes. c Conservation of the amino acid affected by the c.627_629del; p.(Gly210del) UCHL1 mutation
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syndrome and raising the possibility that this gene is also 
contributing to mitochondrial protein quality control.
In contrast to previously described cases, however, 
the siblings in this study both presented with the addi-
tional clinical feature of hypertrophic cardiomyopathy. 
Specifically, both patients demonstrated globally hyper-
trophied left ventricles in the absence of acquired causes 
of ventricular dysfunction (e.g., hypertension, myocardial 
ischaemia, valve dysfunction, prior exposure to toxins, 
and environmental pathogens). In addition, detailed fam-
ily history failed to identify other family members known 
or suspected to be affected by a myocardial disease. The 
tissue distribution of UCHL1 is predominantly within 
the nervous system, although it is also expressed at low 
levels in gonadal cells [23]. Interestingly, UCHL1 is also 
upregulated in other cells under specialized conditions, 
for example in fibroblasts during wound healing and in 
pancreatic, colorectal, medullary thyroid, and breast can-
cer cells [24–27]. In these conditions, it is suggested that 
deregulation of the ubiquitin–proteasome system (UPS) 
may lead to uncontrolled cell growth. Furthermore, the 
UPS plays a key role in maintaining protein homeostasis 
and cardiac function, and UCHL1 has been shown to play 
a key role in this regulation. Knockdown of UCHL1 in 
cardiomyocytes and mouse hearts rescued cardiac hyper-
trophy induced by agonist or pressure overload, and over-
expression resulted in the opposite effect [28]. We have not 
carried out functional studies of mutated UCHL1 protein 
(p.Gly210del). The Glycine residue at position 210 is close 
to the C-terminus, which regulates protein aggregation and 
stability [29]. The removal of the final four amino acids 
from the C-terminus renders the protein insoluble and 
abolishes binding to ubiquitin substrates [30]. Glycine at 
position 210 is located just upstream of the final beta-sheet 
and may have an impact on protein folding and stabil-
ity. Further studies will be required to ascertain how the 
c.627_629del; p.(Gly210del) UCHL1 mutation might lead 
to clinical hypertrophic cardiomyopathy. We recognize 
that it is not possible to completely exclude an alternative 
genetic or acquired cause for hypertrophic cardiomyopathy 
in these siblings, or an unrecognized cardiac disease in 
previous family members. Nonetheless, the presentation 
in these cases raises the possibility that hypertrophic car-
diomyopathy may be an additional feature of the clinical 
syndrome associated with UCHL1 mutations. The sudden 
cardiac death in both patients highlights the importance 
of cardiac follow-up and treatment in neurodegenerative 
disease associated with UCHL1 mutations.
In summary, we have reported on a novel UCHL1 dele-
tion, resulting in a progressive neurodegenerative syndrome. 
The additional feature of hypertrophic cardiomyopathy has 
not been previously described. Cardiac evaluation is, there-
fore, essential in cases with this rare neurological phenotype.
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